Toggle Nav

MOG (35-55)

Catalog No.
A8306
Minor component of CNS myelin
Grouped product items
SizePriceStock Qty
1mg
$98.00
In stock
5mg
$294.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

MOG (35-55) is a truncated peptide derived from the human Myelin Oligodendrocyte Glycoprotein (MOG). MOG, a member of the immunoglobulin superfamily, is expressed wildly in the central nervous system. In mouse and rat models for human multiple sclerosis, MOG is involved in inducing the experimental autoimmune encephalomyelitis. Humoral auto-immunity to the myelin oligodendrocyte glycoprotein (MOG) may be associated with the pathogenesis of multiple sclerosis (MS) [1].

MOG (35-55) is involved in inducing autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination [2]. In HLA-DR2-transgenic mice, Myelin oligodendrocyte glycoprotein-35-55 peptide induced severe chronic experimental autoimmune encephalomyelitis [3].MOG35-55 was highly encephalitogenic and could induce strong T and B cell responses in rats [4]. In NOD/Lt mice (H-2g7) and C57BL/6 mice (H-2b), single injection of MOG35-55 in CFA could induce MS-like disease [4].

References:
[1]. De March A K, De Bouwerie M, Kolopp-Sarda M N, et al. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis[J]. Journal of neuroimmunology, 2003, 135(1): 117-125.
[2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.
[3]. Rich C, Link J M, Zamora A, et al. Myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice[J]. European journal of immunology, 2004, 34(5): 1251-1261.
[4]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageDesiccate at -20°C
M.Wt2581.97
Cas No.149635-73-4
FormulaC118H177N35O29S
Solubility≥32.25mg/mL in H2O, ≥86 mg/mL in DMSO,insoluble in EtOH
Chemical Name(S)-2-((Z)-((2S,3R)-3-amino-1,2-dihydroxy-4-phenylbutylidene)amino)-4-methylpentanoic acid compound with 2,2,2-trifluoroacetic acid (1:1)
SDFDownload SDF
Canonical SMILESCC(C[[email protected]@](/N=C(O)/[[email protected]](O)([H])[[email protected]@](N)([H])CC1=CC=CC=C1)([H])C(O)=O)C.FC(F)(F)C(O)=O
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Protocol

Cell experiment [1]:

Cell lines

Brain endothelial cells

Preparation method

The solubility of this compound in sterile water is 0.50 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0 ~ 50 μg/mL; 48 hrs

Applications

MOG (35-55) significantly decreased the protein concentration in a dose-dependent manner. In cells treated with MOG (35-55) (50 μg/mL) + CFA + PTX, the protein concentration decreased to 37.6% of the level in the CON cells. At the doses of 25 or 50 μg/mL, MOG (35-55) emulsion substantially increased the activities of NADPH oxidase and MMP-9 (44.1 ~ 48.5% and 2-fold higher than those in the CON cells, respectively).

Animal experiment [2]:

Animal models

C57BL/6 mice

Dosage form

50, 100 or 150 μg; s.c.

Applications

At the doses of 50 and 100 μg, MOG (35-55) induced more dramatic weight losses during the course of the MS-like disease, when compared with mice injected with 150 μg MOG (35-55). At day 17 after treatment, 3/5 mice in the 50 μg MOG (35-55) group were moribund whereas 4/5 mice still survived in the 100 and 150 μg dose groups. However, no clinical sign and disease progression were observed in these 3 groups of mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Seo JE, Hasan M, Rahaman KA, Kang MJ, Jung BH, Kwon OS. A leading role for NADPH oxidase in an in-vitro study of experimental autoimmune encephalomyelitis. Mol Immunol. 2016 Apr;72:19-27.

[2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.

Quality Control

Chemical structure

MOG (35-55)

Related Biological Data

MOG (35-55)